Kessler Topaz is currently investigating claims against Amgen Inc. for potential violations of state law and/or federal laws related to pricing for its rheumatoid arthritis prescription medication, Enbrel. Specifically, Kessler Topaz is investigating whether Amgen Inc. violated state and/or federal laws in connection with the significant inflation of Enbrel’s list price over the past several years. For example, Amgen Inc. has raised the price of Enbrel 28 times since acquiring the drug in 2002. In 2021, a single 50 mg dose of Enbrel was priced at $1,389.24 -- 457% higher than when the drug was first acquired by Amgen Inc. For a patient prescribed a standard dose, this translates into a price of approximately $5,560 per month or $72,200 annually. As a result, consumers were forced to pay an unfair and unconscionable price for Enbrel.
Please contact us today to discuss your rights if you have taken Enbrel at any time from 2015 to the present. You may contact us at 484-270-1453, or you can fill out our online form below, or by email at info@ktmc.com.